These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 23391115

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
    Ito T, Lee L, Jensen RT.
    Expert Opin Pharmacother; 2016 Nov; 17(16):2191-2205. PubMed ID: 27635672
    [Abstract] [Full Text] [Related]

  • 23. Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
    Barna ME, Uomo I, Pastorello M.
    JOP; 2013 Jan 10; 14(1):102-4. PubMed ID: 23306347
    [No Abstract] [Full Text] [Related]

  • 24. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
    Capdevila J, Tabernero J.
    Cancer Discov; 2011 Aug 10; 1(3):213-21. PubMed ID: 22586573
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
    Ito T, Igarashi H, Jensen RT, Takayanagi R.
    Fukuoka Igaku Zasshi; 2012 Jul 10; 103(7):131-7. PubMed ID: 22978065
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Dimou AT, Syrigos KN, Saif MW.
    JOP; 2010 Mar 05; 11(2):135-8. PubMed ID: 20208321
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Sunitinib in pancreatic neuroendocrine tumors.
    Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P, Faivre S.
    Target Oncol; 2012 Jun 05; 7(2):117-25. PubMed ID: 22661319
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Systemic therapy for advanced pancreatic neuroendocrine tumors: an update.
    Reidy-Lagunes DL.
    J Natl Compr Canc Netw; 2012 Jun 01; 10(6):777-83. PubMed ID: 22679119
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E, Faivre S.
    Target Oncol; 2012 Sep 01; 7(3):173-81. PubMed ID: 22923165
    [Abstract] [Full Text] [Related]

  • 38. New therapeutic options for metastatic malignant insulinomas.
    de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA.
    Clin Endocrinol (Oxf); 2011 Sep 01; 75(3):277-84. PubMed ID: 21649688
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Real-world study of everolimus in advanced progressive neuroendocrine tumors.
    Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G.
    Oncologist; 2014 Sep 01; 19(9):966-74. PubMed ID: 25117065
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.